Tolstanova Ganna, Deng Xiaoming, Ahluwalia Amrita, Paunovic Brankica, Prysiazhniuk Alona, Ostapchenko Lyudmyla, Tarnawski Andrzej, Sandor Zsuzsanna, Szabo Sandor
VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA.
Educational-Scientific Center "Institute of Biology", Taras Shevchenko National University of Kyiv, Kiev, Ukraine.
Dig Dis Sci. 2015 Oct;60(10):2963-75. doi: 10.1007/s10620-015-3698-5. Epub 2015 May 14.
VEGF-induced vascular permeability and blood vessels remodeling are key features of inflammatory bowel disease (IBD) pathogenesis. Dopamine through D2 receptor (D2R) inhibits VEGF/VPF-mediated vascular permeability and angiogenesis in tumor models. In this study, we tested the hypothesis that pathogenesis of IBD is characterized by the disturbance of dopaminergic system and D2R activity.
IL-10 knockout (KO) mice and rats with iodoacetamide-induced ulcerative colitis (UC) were treated intragastrically with D2R agonists quinpirole (1 mg/100 g) or cabergoline (1 or 5 µg/100 g). Macroscopic, histologic, and clinical features of IBD, colonic vascular permeability, and angiogenesis were examined.
Although colonic D2R protein increased, levels of tyrosine hydroxylase and dopamine transporter DAT decreased in both models of IBD. Treatment with quinpirole decreased the size of colonic lesions in rats with iodoacetamide-induced UC (p < 0.01) and reduced colon wet weight in IL-10 KO mice (p < 0.05). Quinpirole decreased colonic vascular permeability (p < 0.001) via downregulation of c-Src and Akt phosphorylation. Cabergoline (5 µg/100 g) reduced vascular permeability but did not affect angiogenesis and improved signs of iodoacetamide-induced UC in rats (p < 0.05).
Treatment with D2R agonists decreased the severity of UC in two animal models, in part, by attenuation of enhanced vascular permeability and prevention of excessive vascular leakage. Hence, the impairment dopaminergic system seems to be a feature of IBD pathogenesis.
血管内皮生长因子(VEGF)诱导的血管通透性增加和血管重塑是炎症性肠病(IBD)发病机制的关键特征。在肿瘤模型中,多巴胺通过D2受体(D2R)抑制VEGF/血管通透因子(VPF)介导的血管通透性和血管生成。在本研究中,我们验证了IBD发病机制的特征是多巴胺能系统和D2R活性紊乱这一假说。
用D2R激动剂喹吡罗(1 mg/100 g)或卡麦角林(1或5 μg/100 g)对白细胞介素10基因敲除(KO)小鼠和碘乙酰胺诱导的溃疡性结肠炎(UC)大鼠进行灌胃治疗。检查IBD的宏观、组织学和临床特征、结肠血管通透性和血管生成情况。
在两种IBD模型中,尽管结肠D2R蛋白增加,但酪氨酸羟化酶和多巴胺转运体DAT的水平均下降。喹吡罗治疗可减小碘乙酰胺诱导的UC大鼠的结肠病变大小(p<0.01),并减轻白细胞介素10基因敲除小鼠的结肠湿重(p<0.05)。喹吡罗通过下调c-Src和Akt磷酸化降低结肠血管通透性(p<0.001)。卡麦角林(5 μg/100 g)可降低血管通透性,但不影响血管生成,并改善碘乙酰胺诱导的UC大鼠的症状(p<0.05)。
在两种动物模型中,用D2R激动剂治疗可减轻UC的严重程度,部分原因是减弱了增强的血管通透性并防止了过度的血管渗漏。因此,多巴胺能系统受损似乎是IBD发病机制的一个特征。